As of 3:59pm ET
| +0.455 / +1.27%|
The 19 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 35.08, with a high estimate of 51.37 and a low estimate of 30.81. The median estimate represents a -3.19% decrease from the last price of 36.24.
The current consensus among 20 polled investment analysts is to Sell stock in Novozymes A/S. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.